Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines to help people with a range of oncologic and dermatologic diseases.

The companys technology targets the VDAC/HK2 system unique to malignant cells.

Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue.Vidacs lead drug, VDA-1102, has successfully completed a phase 2b clinical trial in actinic keratosis (AK) as an investigational new drug under the FDA and is currently in a phase 2a clinical trial in CTCL in Israel.The company is also developing VDA-1275, a potent small-molecule new chemical entity that selectively modulates the novel VDAC/HK2 mechanism of action.

It is highly potent in vitro against a broad range of tumor types and demonstrates significant selectivity for the VDAC/HK2 system over the VDAC/HK1 system.

VDA-1275 is chemically unrelated to VDA-1102 and presents a different set of pharmacokinetic characteristics.

It is being developed as a systemic drug for the treatment of solid tumors.Vidac was founded by Professor Max Herzberg.

The company has licensed part of its technology from Tel Aviv University and Ben Gurion University.